Hematology Research Articles & Analysis
15 news found
RTsafe, a leading medical technology company specialising in quality assurance (QA) solutions for radiation therapy, and Icon Group (Icon), a leading integrated cancer care provider with a global reach across Australia, New Zealand, ASEAN, Mainland China and the United Kingdom, today announced the purchase of two RTsafe PRIME phantoms. These are the first PRIME phantoms to be installed in ...
ByRTsafe
Results from the study were featured in a poster presentation as Abstract 2171 at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition on December 10, 2022 and have been published online at Blood®. ...
Preclinical data presented at the 2020 Society for Immunotherapy of Cancer’s annual meeting and the 2022 American Association for Cancer Research annual meeting demonstrate that IO-108 functions as a myeloid checkpoint inhibitor and promotes innate and adaptive anti-cancer immunity. ...
Preclinical data presented at the 2020 Society for Immunotherapy of Cancer’s annual meeting and the 2022 American Association for Cancer Research annual meeting demonstrate that IO-108 functions as a myeloid checkpoint inhibitor and promotes innate and adaptive anti-cancer immunity. ...
Additional assets in Immune-Onc’s pipeline include IO-106, a first-in-class antagonist antibody targeting LAIR1 for collagen-rich solid tumors, and multiple undisclosed programs for solid tumors and hematologic malignancies. The company has strategic research collaborations with The University of Texas, Albert Einstein College of Medicine, and Memorial ...
” ABOUT LAIR1 LAIR1 is an immune inhibitory receptor of the Leukocyte Immunoglobulin-Like Receptor subfamily B (LILRB) and is expressed on lymphocytes and myeloid cells. Research shows that LAIR1 expression correlates with worse survival in several cancers. ...
“Immune-Onc was founded on groundbreaking science that first illuminated the role of the previously unexplored LILRB family of myeloid checkpoints in cancer. This research has rapidly advanced a completely new field of study and class of cancer immunotherapy that goes beyond T cells to overcome immune resistance and the limitations of current treatment options. ...
LILRB4 is also expressed on certain hematologic cancer cells. Immune-Onc and The University of Texas published pioneering research in Nature illuminating the role of LILRB4 in immune suppression and tumor infiltration in acute myeloid leukemia (AML) and presented the rationale for targeting LILRB4 in solid tumors at the 2021 American Association for Cancer ...
Guido Marcucci, MD, Chair and Professor, Department of Hematologic Malignancies Translational Science; Director, Gehr Family Center for Leukemia Research, and Chief of Leukemia Division within the Department of Hematology & Hematopoietic Cell Transplantation, City of Hope; and Principal Investigator for the myCare-023 clinical trial. ...
Jeff Sharman is a practicing hematologist/oncologist at the Willamette Valley Cancer Institute and Research Center in Eugene, Oregon. He serves as the medical director of hematology research for the US Oncology network where he has helped build one of the largest clinical research groups studying blood cancer. ...
The latest call for proposals aims to provide funding for clinical research programs that leverage NGS in solid tumors and hematology-oncology applications. The Oncomine Clinical Research Grant awards independent clinical research proposals with up to $200,000 in reagents and general funding. ...
The HemoScreen will be a key piece of research equipment in our cohort study." RURAL plans to deploy HemoScreen hematology analyzers within the MEU lab to do phenotypic measurements in a non-clinical research setting in the rural south, and to test the performance characteristics of the HemoScreen in this setting. ...
He is a physician-scientist in the Department of Medicine, Division of Hematology/Oncology directing both a translational research program and a research lab. He has focused on cancer immunotherapy for over 20 years and has been involved in both pre-clinical and clinical studies of FDA-approved immunotherapies including sipuleucel-T and immune ...
In hematology oncology, it is critically important to understand the genetics driving acute malignancies to quickly determine how best to address the disease. ...
"We have heard significant interest from our customers in the potential to run our Oncomine Myeloid Research Assay on the new platform. Delivering on that need will mean that hematology and oncology labs can quickly get the results they need." Expanded Portfolio Addresses Full Range of Hematology Applications Thermo Fisher also announced an ...